ICAAC, the Inter-Science Conference on Antimicrobial Agents and Chemotherapy, was held this year in San Diego, September 27-30. This annual conference focuses mainly on the development of new antibiotics and antivirals. On October 11 HIVandHepatitis.c
On October 11 Roche and Trimeris, Inc. announced that the FDA had granted priority review to FUZEON (TM) (generic name enfuvirtide, formerly known as T-20). This means that the FDA plans to review the application for approval in six months, and announ
All the approved HIV treatments so far are antiretrovirals--drugs that directly target some step in viral replication. In the future we may have another kind of treatment, immune-based therapy, which strengthen the immune system's ability to control H
On September 27 over 80 health experts and organizations released a letter warning against all rectal use of nonoxynol-9 (N-9)--a spermicide mistakenly used to kill HIV, when actually it makes transmission worse. The letter came after a quiet campaign
Dr. Wan Yan Hai, the AIDS activist detained by Chinese security on August 24, (see AIDS Treatment News #383, September 6, 2002) was unexpectedly released in Beijing on September 20. His release came after United Nations and the U.S. State Department o
ACT UP and several co-sponsors have called for a peaceful protest at the White House on November 26, less than a week before World AIDS Day, to demand Federal action against AIDS in the U.S. and worldwide. Demonstrators will meet at noon at McPherson
Patients and physicians should know that researchers working on at least a dozen projects funded by the U.S. National Institutes of Health need tissue from persons with HIV for medical research. This includes important studies of viral reservoirs, as
In a new approach to HIV prevention, the Bill & Melinda Gates Foundation will fund a multinational trial of the antiretroviral drug tenofovir, taken orally once daily by HIV negative persons at high risk, to see if it can prevent HIV infection. The st
The new Vaccine Research Center at the U.S. National Institute of Allergy and Infectious Diseases is starting the first human trial of its vaccine candidate, developed to target HIV clades (subtypes) A, B, and C. Together these subtypes are responsibl
In an important study reported this month, in which almost 28,000 healthy U.S. women were followed for eight years, the level of C-reactive protein, a marker of inflammation, was a better predictor than LDL cholesterol of first heart attack or related
In 2003 researchers stopped a clinical trial abruptly when they found that a combination of three drugs that seemed likely to work well together failed to control the virus in many patients, and led to a very high rate of viral resistance; a comparison regimen that used efavirenz instead of the tenofovir worked well. A similar combination (tenofovir plus abacavir plus ddI) also failed. However, regimens that include AZT do not fail in this way. The problem was completely unexpected, and since it occurred, several different theories were proposed.
No one knows the answer for sure--and we will probably never know, since it would be unethical to test the failed triple combinations in patients with HIV. But many researchers now believe the most likely explanation is that the drug combinations failed to control the virus because of a low genetic barrier to HIV resistance. Two mutations that developed in this trial protect the virus against the three drugs.
The December 1, 2005 Journal of Infectious Diseases published the full report of the trial [1] and a commentary [2]; both are available free online.
"The most likely explanation is the low genetic barrier to resistance produced by synergistic selection pressure from all 3 drugs for 2 point mutation, M184V and K65R. Both abacavir and tenofovir DF select for the K65R mutation, which reduces susceptibility to both drugs, as well as to lamivudine [3TC]. M184V is selected for by lamivudine and abacavir, and it decreases susceptibility to both. Thus, the selection of 2 mutations, each of which may preexist as minority species, leads to virologic failure with this regimen." [1]
The authors conclude that physicians should not try new combinations on their own as the first antiretroviral treatment for patients. "Given the growing number of potent, well-studied combinations now available, there is no longer a rationale for the use of untested regimens outside of clinical trials in the treatment of therapy-naive HIV-infected patients." [1]
References
Note: Both articles below were made available free online by the journal; you do not need to be a subscriber.
They are available through the Table of Contents of the December 1 issue, http://www.journals.uchicago.edulJID/journal/contents/v192n11.html
(1.) Gallant JE, Rodriguez AE, Weinberg WG, and others. for the ESS30009 study. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. Journal of Infectious Diseases. December 1,2005; volume 192, pages 1921-1930.
(2.) Kuritzkes DR. Less than the sum of its parts: Failure of a tenofovir-abacavir-lamivudine triple-nucleoside regimen. Editorial commentary. Journal of Infectious Diseases. December 1,2005; volume 192, pages 1867-1868.
COPYRIGHT 2005 John S. JamesCOPYRIGHT 2005 Gale Group